The global healthcare technology leader has successfully finalized the acquisition of 100% of the share capital of the target, marking a significant reinforcement of its ophthalmic instrument capabilities within the Healthcare division. The aim objective for Halma in this transaction, is the strategic desire to internalize the production of high-precision disposables, thereby insulating the parent entity's supply chain against external volatility. The industrial logic hinges on the fusion of the target’s automated sharpening technologies with the acquirer’s clinical reach, ensuring a "gold-standard" edge consistency for elite ophthalmic teams. The industrial logic hinges on the fusion of the target’s automated sharpening technologies with the acquirer’s clinical reach, ensuring a "gold-standard" edge consistency for elite ophthalmic teams. Rather than a simple capacity increase, the move acts as a catalyst for product synergy, mapping a specialized catalog of blades and cannulas onto a global direct-sales infrastructure.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.